This year’s BIO International Convention is unlike any other - are you ready to make the most of connecting virtually with potential partners, investors and industry peers? As an entrepreneur, it’s vital to optimize this unique, virtual opportunity by having a solid game plan, as well as an effective pitch deck and pitching strategy. Join us for a discussion on how to best prepare for your virtual BIO experience.
Topics Include:
How to navigate and network virtually
Deciding who to meet
Virtual meeting and pitching strategies
Pre and post event connecting and follow-up best practices
With 18+ years of expertise in event and association marketing, Erin is passionate about creating memorable customer experiences and impactful business development events around the world.
Erin leads the BIO marketing team with a sharp focus on customer experience, lead generation, attendee acquisition, branding, event strategy, international recruitment, social media marketing and more. Erin’s team oversees marketing for a portfolio of events for BIO (ranging in size and sector from 100 – 18,000 in attendance) in addition to BIO’s products and services.
David H. Crean, Ph.D is a Managing Director at Objective Capital Partners, where he leads the firm’s M&A, partnering, valuations and capital financing transactions with life science and healthcare clients. Dr. Crean has in excess of 25 years of life sciences R&D and corporate development transactional experience in the healthcare and biopharma industries responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC.
Dr. Stolz has spent more than 15 years in executive positions in business and corporate development and operations in both large and small biopharmaceutical companies. Most recently she was Chief Business Officer at Annexon Biosciences and prior that she spent 5 years at Johnson & Johnson Innovation negotiating transactions and running the West coast JLABS business. She has over 25 years of industry experience working for companies that have been both technology platform and therapeutics focused.
Tim Herpin is Vice-President, Janssen Business Development, Infectious Diseases and Vaccines. In this role, he leads the strategy and planning of all business development activities in support of Janssen’s Infectious Diseases and Vaccines therapeutic area. Before joining Johnson & Johnson, Tim spent more than 15 years in Business Development roles in biotech and pharmaceutical companies. He was the Chief Business Officer at Caribou Biosciences, a privately held gene editing company based in the Bay Area. Prior to that, Tim was Vice-President, Head of Transactions at AstraZeneca and led a group of business development professionals involved in all aspects of transaction negotiation and execution.
